Cell Therapy for Sarcoma
Recruiting at43 trial locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Adaptimmune
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Research Team
GC
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Eligibility Criteria
This trial is for people over 10 years old with advanced synovial sarcoma or myxoid/round cell liposarcoma, which are types of tumors. Participants must have certain HLA-A2 genes and their tumor must express NY-ESO-1. They should be relatively healthy (good performance status) and not have had severe autoimmune diseases, previous specific cancer treatments, major surgery within the last month, or other serious health issues.Inclusion Criteria
My genetic test shows I have HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06.
My tumor is positive for NY-ESO-1.
I am mostly active and can carry out daily activities with little to no help.
See 5 more
Exclusion Criteria
Prior radiation exceeds protocol specified limits
My cancer has spread to my brain.
I have a cancer that is not fully in remission.
See 9 more
Treatment Details
Interventions
- Lete-Cel (CAR T-cell Therapy)
Trial OverviewThe study tests Letetresgene autoleucel (lete-cel), a type of engineered T-cell therapy designed to target cancer cells in patients with specific genetic markers. It's part of a larger study on human-engineered T-cell therapies. Patients will also receive Cyclophosphamide and Fludarabine as part of the treatment process.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Letetresgene autoleucelExperimental Treatment3 Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Adaptimmune
Lead Sponsor
Trials
25
Recruited
10,000+
GlaxoSmithKline
Lead Sponsor
Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Related Searches
By Condition